Immuneering Corporation Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Immuneering Corporation (IMRX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$165.24 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-05
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$165.24K.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$322.34K.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-09-30 was $7.84K, a 0.26% increase year-over-year.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2024-06-30 was $1.08K.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $81.33K, a 10353.98% increase from fiscal 2024.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was $778.00, a 97.35% decline from fiscal 2023.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $29.34K, a 55.34% increase from fiscal 2022.
- Immuneering Corporation other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $18.89K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$165.24K 10-Q · filed 2026-08-05 | -$487.57K derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$322.34K 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $81.33K 10-K · filed 2026-03-06 | |||
| 2024-12-31 | $778.00 10-K · filed 2026-03-06 | |||
| 2024-09-30 | $7.84K 10-Q · filed 2025-11-12 | $8.93K derived: sum of 2 quarters · filed 2025-11-12 | $8.62K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.08K 10-Q · filed 2025-11-12 | $778.00 derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | -$306.00 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $29.34K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $7.83K 10-Q · filed 2024-11-13 | $5.10K derived: sum of 2 quarters · filed 2024-11-13 | $35.73K derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$2.72K 10-Q · filed 2024-11-13 | $27.90K derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $30.63K 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $18.89K 10-K · filed 2024-03-01 | |||
| 2022-09-30 | $39.09K 10-Q · filed 2023-11-09 | $24.92K derived: sum of 2 quarters · filed 2023-11-09 | -$93.46K derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$14.17K 10-Q · filed 2023-11-09 | -$132.55K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | -$118.39K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |